Your browser doesn't support javascript.
loading
Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia.
van der Ham, Cédric G; Suurenbroek, Lianne C; Kleisman, Michelle M; Antic, Zeljko; Lelieveld, Stefan H; Yeong, Marley; Westera, Liset; Sonneveld, Edwin; Hoogerbrugge, Peter M; van der Velden, Vincent H J; van Leeuwen, Frank N; Kuiper, Roland P.
Afiliación
  • van der Ham CG; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Suurenbroek LC; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Kleisman MM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Antic Z; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Lelieveld SH; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Yeong M; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Westera L; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Sonneveld E; Dutch Childhood Oncology Group, Utrecht, The Netherlands.
  • Hoogerbrugge PM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • van der Velden VHJ; Dutch Childhood Oncology Group, Utrecht, The Netherlands.
  • van Leeuwen FN; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Kuiper RP; Dutch Childhood Oncology Group, Utrecht, The Netherlands.
Leukemia ; 2024 Sep 04.
Article en En | MEDLINE | ID: mdl-39232206
ABSTRACT
Pediatric acute lymphoblastic leukemia (ALL) is marked by low mutational load at initial diagnosis, which increases at relapse. To determine which processes are active in (relapsed) ALL and how they behave during disease progression before and after therapy, we performed whole genome sequencing on 97 tumor samples of 29 multiply relapsed ALL patients. Mutational load increased upon relapse in 28 patients and upon every subsequent relapse in 22 patients. In addition to two clock-like mutational processes, we identified UV-like damage, APOBEC activity, reactive oxygen species, thiopurine-associated damage and an unknown therapy component as drivers of mutagenesis. Mutational processes often affected patients over longer time periods, but could also occur in isolated events, suggesting the requirement of additional triggers. Thiopurine exposure was the most prominent source of new mutations in relapse, affecting over half of the studied patients in first and/or later relapse and causing potential relapse-driving mutations in multiple patients. Our data demonstrate that multiple mutational processes frequently act in parallel as prominent secondary drivers with dynamic activity during ALL development and progression.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos